The risk score was built from variables that measured the cardiac and neurological status regardless of mutation type. Therefore, our proposed score should be useful to gauge the risk of patients with rare variants of TTR and to take into account the phenotypic variability encountered among patients with a similar mutation. The study population was representative of a region where ATTR is not endemic and the 74% 5-year survival of our patients in line with the 77% previously reported (3). Previous reports
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suggested that septum thickness could be associated with a worse prognosis in ATTR patients with a liver transplant (4). Wide QRS complexes on electrocardiography were associated with an independent increased risk of death in our study, and this was consistent with the high frequency of conduction disorders in transthyretin cardiac amyloidosis.
The predictive model was internally validated by the bootstrap method, but further prospective studies will be required to confirm its external validity. Survival of ATTR patients after liver transplantation differs significantly according to the score (log-rank test: p < 0.0001). For high-risk patients (score <50%), the 1-year survival rate was 70% and the 5-year survival rate was 31%. ATTR ¼ transthyretin amyloidosis. Please note: Dr. Mestres has served on the clinical events committee of Edwards Lifesciences; and has served on the speakers bureau of On-X Life Technologies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
